JP7062754B2 - haNKセツキシマブ併用及び方法 - Google Patents
haNKセツキシマブ併用及び方法 Download PDFInfo
- Publication number
- JP7062754B2 JP7062754B2 JP2020508476A JP2020508476A JP7062754B2 JP 7062754 B2 JP7062754 B2 JP 7062754B2 JP 2020508476 A JP2020508476 A JP 2020508476A JP 2020508476 A JP2020508476 A JP 2020508476A JP 7062754 B2 JP7062754 B2 JP 7062754B2
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- composition
- cell
- antibody
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005395 cetuximab Drugs 0.000 title claims description 23
- 238000000034 method Methods 0.000 title description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 148
- 239000000203 mixture Substances 0.000 claims description 87
- 210000004027 cell Anatomy 0.000 claims description 78
- 238000011282 treatment Methods 0.000 claims description 69
- 230000001472 cytotoxic effect Effects 0.000 claims description 54
- 231100000433 cytotoxic Toxicity 0.000 claims description 53
- 239000000427 antigen Substances 0.000 claims description 49
- 102000036639 antigens Human genes 0.000 claims description 49
- 108091007433 antigens Proteins 0.000 claims description 49
- 210000003850 cellular structure Anatomy 0.000 claims description 34
- 229940124856 vaccine component Drugs 0.000 claims description 30
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 229950004775 aldoxorubicin Drugs 0.000 claims description 26
- OBMJQRLIQQTJLR-USGQOSEYSA-N n-[(e)-[1-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\CO)=N\NC(=O)CCCCCN1C(C=CC1=O)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 OBMJQRLIQQTJLR-USGQOSEYSA-N 0.000 claims description 26
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 24
- 230000003308 immunostimulating effect Effects 0.000 claims description 24
- 241000700605 Viruses Species 0.000 claims description 23
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 22
- 150000007523 nucleic acids Chemical class 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 102000003812 Interleukin-15 Human genes 0.000 claims description 18
- 108090000172 Interleukin-15 Proteins 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 241000894006 Bacteria Species 0.000 claims description 17
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 14
- 229960004679 doxorubicin Drugs 0.000 claims description 14
- 102000004127 Cytokines Human genes 0.000 claims description 13
- 108090000695 Cytokines Proteins 0.000 claims description 13
- 230000005746 immune checkpoint blockade Effects 0.000 claims description 13
- 230000002483 superagonistic effect Effects 0.000 claims description 12
- 108010057840 ALT-803 Proteins 0.000 claims description 11
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 11
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 11
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 11
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 10
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 10
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 9
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 9
- 229960000397 bevacizumab Drugs 0.000 claims description 9
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 9
- 108020003175 receptors Proteins 0.000 claims description 9
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 102000000588 Interleukin-2 Human genes 0.000 claims description 8
- 229950002916 avelumab Drugs 0.000 claims description 8
- 229960004397 cyclophosphamide Drugs 0.000 claims description 8
- 229960000513 necitumumab Drugs 0.000 claims description 8
- 230000006444 vascular growth Effects 0.000 claims description 8
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims description 7
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 7
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 7
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 7
- 102100034256 Mucin-1 Human genes 0.000 claims description 7
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 7
- 239000005557 antagonist Substances 0.000 claims description 7
- 229960001592 paclitaxel Drugs 0.000 claims description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 6
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 6
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 6
- 101001068136 Homo sapiens Hepatitis A virus cellular receptor 1 Proteins 0.000 claims description 6
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 6
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 238000011518 platinum-based chemotherapy Methods 0.000 claims description 6
- 102100023727 Mitochondrial antiviral-signaling protein Human genes 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000009169 immunotherapy Methods 0.000 claims description 5
- WCZDQPXNBJTKPI-UHFFFAOYSA-O Cyanidin 7-glucoside Chemical compound OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C(C=C(O)C(=[O+]2)C=3C=C(O)C(O)=CC=3)C2=C1 WCZDQPXNBJTKPI-UHFFFAOYSA-O 0.000 claims description 4
- 101000953492 Homo sapiens Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 1 Proteins 0.000 claims description 4
- 102000013462 Interleukin-12 Human genes 0.000 claims description 4
- 108010065805 Interleukin-12 Proteins 0.000 claims description 4
- 101150113776 LMP1 gene Proteins 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 108010074108 interleukin-21 Proteins 0.000 claims description 4
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 3
- 235000008191 folinic acid Nutrition 0.000 claims description 3
- 239000011672 folinic acid Substances 0.000 claims description 3
- 229960001691 leucovorin Drugs 0.000 claims description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960004117 capecitabine Drugs 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 238000012423 maintenance Methods 0.000 description 27
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 21
- 229960005486 vaccine Drugs 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 238000007920 subcutaneous administration Methods 0.000 description 16
- 229940022399 cancer vaccine Drugs 0.000 description 15
- 238000009566 cancer vaccine Methods 0.000 description 15
- 210000000822 natural killer cell Anatomy 0.000 description 15
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 14
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 14
- 201000002528 pancreatic cancer Diseases 0.000 description 14
- 208000008443 pancreatic carcinoma Diseases 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 230000001939 inductive effect Effects 0.000 description 12
- 206010061289 metastatic neoplasm Diseases 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 10
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 238000011269 treatment regimen Methods 0.000 description 10
- 230000028993 immune response Effects 0.000 description 9
- 230000001394 metastastic effect Effects 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 210000002865 immune cell Anatomy 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 7
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 7
- 206010021143 Hypoxia Diseases 0.000 description 7
- 238000002659 cell therapy Methods 0.000 description 7
- 230000001146 hypoxic effect Effects 0.000 description 7
- 230000037449 immunogenic cell death Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 229940127557 pharmaceutical product Drugs 0.000 description 7
- 102000016914 ras Proteins Human genes 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 6
- RMSWBHUVFNFNIZ-ZETCQYMHSA-N n-{(4s)-4-amino-5-[(2-aminoethyl)amino]pentyl}-n'-nitroguanidine Chemical compound NCCNC[C@@H](N)CCCNC(=N)N[N+]([O-])=O RMSWBHUVFNFNIZ-ZETCQYMHSA-N 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010062016 Immunosuppression Diseases 0.000 description 5
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 5
- 238000011260 co-administration Methods 0.000 description 5
- 238000002591 computed tomography Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 5
- 230000001506 immunosuppresive effect Effects 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000002720 stereotactic body radiation therapy Methods 0.000 description 5
- 238000011285 therapeutic regimen Methods 0.000 description 5
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000033289 adaptive immune response Effects 0.000 description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- DTMGIJFHGGCSLO-FIAQIACWSA-N ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate Chemical class CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC.CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC DTMGIJFHGGCSLO-FIAQIACWSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 208000037821 progressive disease Diseases 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 4
- 229960000977 trabectedin Drugs 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000581 natural killer T-cell Anatomy 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 238000011255 standard chemotherapy Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000031998 transcytosis Effects 0.000 description 3
- 231100000402 unacceptable toxicity Toxicity 0.000 description 3
- -1 Brachyuri Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 2
- 101000773038 Human herpesvirus 7 (strain RK) U21 glycoprotein Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102000000704 Interleukin-7 Human genes 0.000 description 2
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 2
- 210000004322 M2 macrophage Anatomy 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 108091023290 ctRNA Proteins 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- KVJWZTLXIROHIL-QDORLFPLSA-N lipid IVA Chemical compound O[C@H]1[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O[C@@H]1CO[C@H]1[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@H](OP(O)(O)=O)[C@@H](CO)O1 KVJWZTLXIROHIL-QDORLFPLSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102200006520 rs121913240 Human genes 0.000 description 2
- 102200006525 rs121913240 Human genes 0.000 description 2
- 102200006531 rs121913529 Human genes 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 108010079555 yeast-CEA vaccine Proteins 0.000 description 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical compound SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102100036008 CD48 antigen Human genes 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 101150082208 DIABLO gene Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 1
- 108010069621 Epstein-Barr virus EBV-associated membrane antigen Proteins 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000669511 Homo sapiens T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 description 1
- 102100034980 ICOS ligand Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710090028 Inositol-3-phosphate synthase 1 Proteins 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 102100039564 Leukosialin Human genes 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710142315 Mitochondrial antiviral-signaling protein Proteins 0.000 description 1
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 102100035488 Nectin-2 Human genes 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 1
- 102100029740 Poliovirus receptor Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101150107869 Sarg gene Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 101800001707 Spacer peptide Proteins 0.000 description 1
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 description 1
- 102100039367 T-cell immunoglobulin and mucin domain-containing protein 4 Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
- 101150071882 US17 gene Proteins 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 108091092259 cell-free RNA Proteins 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- PJZDLZXMGBOJRF-CXOZILEQSA-L folfirinox Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PJZDLZXMGBOJRF-CXOZILEQSA-L 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000032832 immune response to tumor cell Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464464—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/46447—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/852—Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/54—Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Developmental Biology & Embryology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
Description
実施例Iで使用される治療組成物及びモダリティには、以下の表1に示すとおりの様々な生体分子及び組成物が含まれる。
Claims (33)
- 腫瘍を有する患者の治療をするための化学療法組成物であって、
ワクチン成分と細胞傷害性細胞成分とを含む免疫療法組成物、抗体および免疫刺激性スーパーカインと組み合わせて使用するための、アルドキソルビシンを含む化学療法組成物であり、
前記ワクチン成分が、ブラキウリ、MUC1、及びCEAからなる群から選択される腫瘍関連抗原であり、
前記細胞傷害性細胞成分が、NK-92誘導体細胞であり、
前記抗体が、セツキシマブであり、かつ
前記免疫刺激性スーパーカインが、ALT803である、
化学療法組成物。 - 腫瘍を有する患者の治療をするための免疫療法組成物であって、
アルドキソルビシンを含む化学療法組成物、抗体および免疫刺激性スーパーカインと組み合わせて使用するための、ワクチン成分と細胞傷害性細胞成分とを含む免疫療法組成物であり、
前記ワクチン成分が、ブラキウリ、MUC1、及びCEAからなる群から選択される腫瘍関連抗原であり、
前記細胞傷害性細胞成分が、NK-92誘導体細胞であり、
前記抗体が、セツキシマブであり、かつ
前記免疫刺激性スーパーカインが、ALT803である、
免疫療法組成物。 - アベルマブ、ベバシズマブ、カペシタビン、シスプラチン、シクロホスファミド、5-FU、ロイコボリン、Nab-パクリタキセルおよびネシツムマブからなる群から選択される少なくとも1つの薬剤をさらに組み合わせて使用するための、請求項1または2に記載の組成物。
- 前記ワクチン成分が、改変細菌、改変酵母、及び改変ウイルスのうちの少なくとも1つを含み、及び前記ワクチン成分が、腫瘍関連抗原をコードする組換え核酸を更に含む、請求項1~3のいずれか一項に記載の組成物。
- 前記ワクチン成分が、改変細菌、改変酵母、及び改変ウイルスのうちの少なくとも2つを含み、及び前記ワクチン成分が、腫瘍関連抗原をコードする組換え核酸を更に含む、請求項4に記載の組成物。
- 前記細胞傷害性細胞成分がhaNK細胞及びT細胞のうちの少なくとも1つを含んでなり、前記haNK細胞又は前記T細胞が、キメラ抗原受容体及びCD16高親和性変異体のうちの少なくとも1つを発現するように遺伝子操作されている、請求項1~5のいずれか一項に記載の組成物。
- 抗体又はチェックポイント阻害に干渉する若しくはそれを下方制御するタンパク質をさらに組み合わせて使用するための、請求項1~6のいずれか一項に記載の組成物。
- 前記抗体が前記細胞傷害性細胞成分にカップリングされる、請求項7に記載の組成物。
- 前記抗体が、成長因子受容体、血管成長受容体、免疫チェックポイント阻害薬、腫瘍関連抗原、腫瘍特異抗原、又は腫瘍特異的及び患者特異的ネオエピトープのうちの少なくとも1つに特異的に結合する、請求項7又は8に記載の組成物。
- チェックポイント阻害に干渉する又はそれを下方制御する前記タンパク質が、CTLA-4、PD-1、TIM1受容体、2B4、又はCD160の抗体又はアンタゴニストである、請求項7~9のいずれか一項に記載の組成物。
- 前記細胞傷害性細胞成分がhaNK細胞及びT細胞のうちの少なくとも1つを含んでなり、前記haNK細胞又は前記T細胞が、キメラ抗原受容体及びCD16高親和性変異体のうちの少なくとも1つを発現するように遺伝子操作されている、請求項1に記載の組成物。
- 抗体又はチェックポイント阻害に干渉する若しくはそれを下方制御するタンパク質をさらに組み合わせて使用するための、請求項1に記載の組成物。
- 前記抗体が前記細胞傷害性細胞成分にカップリングされる、請求項12に記載の組成物。
- 前記抗体が、成長因子受容体、血管成長受容体、免疫チェックポイント阻害薬、腫瘍関連抗原、腫瘍特異抗原、又は腫瘍特異的及び患者特異的ネオエピトープのうちの少なくとも1つに特異的に結合する、請求項12又は13に記載の組成物。
- チェックポイント阻害に干渉する又はそれを下方制御する前記タンパク質が、CTLA-4、PD-1、TIM1受容体、2B4、又はCD160の抗体又はアンタゴニストである、請求項12~14のいずれか一項に記載の組成物。
- 前記腫瘍が固形腫瘍である、請求項1~15のいずれか一項に記載の組成物。
- 免疫刺激性サイトカイン又は免疫刺激性スーパーカインをさらに組み合わせて使用するための、請求項1~16のいずれか一項に記載の組成物。
- 前記免疫刺激性サイトカイン又は免疫刺激性スーパーカインが、IL-2、IL-12、IL-15、IL-15スーパーアゴニスト、IL-21、IPS1、及びLMP1からなる群から選択される、請求項17に記載の組成物。
- 前記ワクチン成分と前記細胞傷害性細胞成分とが少なくとも1日空けて投与される、請求項1~18のいずれか一項に記載の組成物。
- 前記患者が、過去の白金系化学療法及び抗PD-1/PD-L1療法のうちの少なくとも一方の治療歴を有する、請求項1~19のいずれか一項に記載の組成物。
- 前記患者の分子プロファイルが決定され、前記分子プロファイルがHER2発現レベル又はRAS突然変異状態を含む、請求項1~20のいずれか一項に記載の組成物。
- 腫瘍を有する患者の治療をするための免疫療法組成物であって、アルドキソルビシンを含む化学療法組成物、抗体および免疫刺激性スーパーカインと組み合わせて使用するための、ワクチン成分と細胞傷害性細胞成分とを含む免疫療法組成物であり、
前記ワクチン成分が、ブラキウリ、MUC1、及びCEAからなる群から選択される腫瘍関連抗原であり、
前記細胞傷害性細胞成分が、NK-92誘導体細胞であり、
前記抗体が、セツキシマブであり、
前記免疫刺激性スーパーカインが、ALT803であり、かつ
前記免疫療法組成物が、成長因子受容体、血管成長受容体、癌関連抗原、癌特異抗原、若しくは癌特異的及び患者特異的ネオエピトープに特異的に結合する抗体又はチェックポイント阻害に干渉する若しくはそれを下方制御するタンパク質を更に含む、
免疫療法組成物。 - 腫瘍を有する患者の治療をするための化学療法組成物であって、ワクチン成分と細胞傷害性細胞成分とを含む免疫療法組成物、抗体および免疫刺激性スーパーカインと組み合わせて使用するための、アルドキソルビシンを含む化学療法組成物であり、
前記ワクチン成分が、ブラキウリ、MUC1、及びCEAからなる群から選択される腫瘍関連抗原であり、
前記細胞傷害性細胞成分が、NK-92誘導体細胞であり、
前記抗体が、セツキシマブであり、
前記免疫刺激性スーパーカインが、ALT803であり、かつ
前記免疫療法組成物が、成長因子受容体、血管成長受容体、癌関連抗原、癌特異抗原、若しくは癌特異的及び患者特異的ネオエピトープに特異的に結合する抗体又はチェックポイント阻害に干渉する若しくはそれを下方制御するタンパク質を更に含む、
化学療法組成物。 - 前記ワクチン成分が、改変細菌、改変酵母、及び改変ウイルスのうちの少なくとも1つを含み、及び前記ワクチン成分が、腫瘍関連抗原をコードする組換え核酸を更に含む、請求項22または23に記載の組成物。
- 前記細胞傷害性細胞成分がhaNK細胞及びT細胞のうちの少なくとも1つを含んでなり、前記haNK細胞又は前記T細胞が、キメラ抗原受容体及びCD16高親和性変異体のうちの少なくとも1つを発現するように遺伝子操作されている、請求項22~24のいずれか一項に記載の組成物。
- 前記細胞傷害性細胞成分が、抗体又はチェックポイント阻害に干渉する若しくはそれを下方制御するタンパク質とカップリングされる、請求項22~25のいずれか一項に記載の組成物。
- 前記抗体が、成長因子受容体、血管成長受容体、免疫チェックポイント阻害薬、腫瘍関連抗原、腫瘍特異抗原、又は腫瘍特異的及び患者特異的ネオエピトープのうちの少なくとも1つに特異的に結合する、請求項26に記載の組成物。
- チェックポイント阻害に干渉する又はそれを下方制御する前記タンパク質が、CTLA-4、PD-1、TIM1受容体、2B4、又はCD160の抗体又はアンタゴニストである、請求項26に記載の組成物。
- 前記ワクチン成分と前記細胞傷害性細胞成分とが、前記患者に共投与されるように製剤化される、請求項22~28のいずれか一項に記載の組成物。
- 前記ワクチン成分と前記細胞傷害性細胞成分とが、前記患者に別々に投与するように製剤化される、請求項22~28のいずれか一項に記載の組成物。
- 免疫刺激性サイトカイン又は免疫刺激性スーパーカインをさらに組み合わせて使用するための、請求項22~30のいずれか一項に記載の組成物。
- 前記免疫刺激性サイトカイン又は免疫刺激性スーパーカインが、IL-2、IL-12、IL-15、IL-15スーパーアゴニスト、IL-21、IPS1、及びLMP1からなる群から選択される、請求項31に記載の組成物。
- 前記患者が、過去の白金系化学療法及び抗PD-1/PD-L1療法のうちの少なくとも一方の治療歴を有する、請求項22~32のいずれか一項に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762545744P | 2017-08-15 | 2017-08-15 | |
US62/545,744 | 2017-08-15 | ||
PCT/US2018/046735 WO2019036485A1 (en) | 2017-08-15 | 2018-08-14 | ASSOCIATIONS OF CÉTUXIMAB AND HIGH AFFINITY NATURAL KILLER CELLS AND ASSOCIATED METHODS |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020531437A JP2020531437A (ja) | 2020-11-05 |
JP7062754B2 true JP7062754B2 (ja) | 2022-05-06 |
Family
ID=65361956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020508476A Active JP7062754B2 (ja) | 2017-08-15 | 2018-08-14 | haNKセツキシマブ併用及び方法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US11510982B2 (ja) |
EP (1) | EP3668538A4 (ja) |
JP (1) | JP7062754B2 (ja) |
KR (3) | KR20200033351A (ja) |
CN (1) | CN110996991A (ja) |
AU (1) | AU2018318125B2 (ja) |
CA (1) | CA3073045A1 (ja) |
WO (1) | WO2019036485A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018318125B2 (en) | 2017-08-15 | 2021-09-09 | Nantcell, Inc. | Hank cetuximab combinations and methods |
WO2020227492A2 (en) * | 2019-05-07 | 2020-11-12 | Board Of Regents, The University Oftexas System | Targeting otub1 in immunotherapy |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19926154A1 (de) | 1999-06-09 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
DE10012120A1 (de) | 2000-03-13 | 2001-09-27 | Ktb Tumorforschungs Gmbh | Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel |
PT2685995T (pt) * | 2011-03-17 | 2017-08-09 | Globeimmune Inc | Composições imunoterapêuticas de levedura-brachyury |
US20150342975A1 (en) | 2012-12-13 | 2015-12-03 | Cytrx Corporation | Anthracycline formulations |
BR112015030623A2 (pt) | 2013-06-05 | 2017-07-25 | Cytrx Corp | agentes citotóxicos para o tratamento de câncer |
CN106456724A (zh) * | 2013-12-20 | 2017-02-22 | 博德研究所 | 使用新抗原疫苗的联合疗法 |
WO2016172249A1 (en) * | 2015-04-20 | 2016-10-27 | Etubics Corporation | Methods and compositions for combination immunotherapy |
EP3954394A1 (en) | 2015-06-19 | 2022-02-16 | Centurion BioPharma Corporation | Delivery systems for controlled drug release |
EP4378957A2 (en) * | 2015-07-29 | 2024-06-05 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
CA3007996A1 (en) * | 2015-12-09 | 2017-06-15 | Nant Holdings Ip, Llc | Compositions and methods for treatment of her2 positive metastatic breast cancer |
EP3464560A4 (en) * | 2016-06-03 | 2020-01-15 | Etubics Corporation | COMPOSITIONS AND METHODS FOR TUMOR VACCINATION AND IMMUNOTHERAPY WITH HER2 / NEU |
EP3621647A1 (en) | 2017-05-11 | 2020-03-18 | Nantkwest, Inc. | Anti-egfr/high affinity nk-cells compositions and methods for chordoma treatment |
AU2018318125B2 (en) | 2017-08-15 | 2021-09-09 | Nantcell, Inc. | Hank cetuximab combinations and methods |
CN111225673A (zh) | 2017-09-06 | 2020-06-02 | 河谷细胞有限公司 | 亚德阿霉素组合治疗及方法 |
-
2018
- 2018-08-14 AU AU2018318125A patent/AU2018318125B2/en not_active Expired - Fee Related
- 2018-08-14 KR KR1020207007502A patent/KR20200033351A/ko not_active Application Discontinuation
- 2018-08-14 CA CA3073045A patent/CA3073045A1/en active Pending
- 2018-08-14 US US16/639,526 patent/US11510982B2/en active Active
- 2018-08-14 KR KR1020237025519A patent/KR20230115351A/ko not_active Application Discontinuation
- 2018-08-14 KR KR1020227016167A patent/KR20220068272A/ko active Application Filing
- 2018-08-14 JP JP2020508476A patent/JP7062754B2/ja active Active
- 2018-08-14 WO PCT/US2018/046735 patent/WO2019036485A1/en unknown
- 2018-08-14 EP EP18846765.8A patent/EP3668538A4/en active Pending
- 2018-08-14 CN CN201880053244.2A patent/CN110996991A/zh active Pending
-
2022
- 2022-09-01 US US17/901,391 patent/US20230000978A1/en active Pending
Non-Patent Citations (3)
Title |
---|
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele,Oncotarget. 2016; 7:86359-86373.,https://doi.org/10.18632/oncotarget.13411 |
CytRx Corporation Announces Global Strategic License With NantCell Inc. For Aldoxorubicin, An Albumin Mediated Chemotherapeutic,CISION PR Newswire, Jul 28, 2017,https://www.prnewswire.com/news-releases/cytrx-corporation-announces-global-strategic-license-with-nantcell-inc-for-aldoxorubicin-an-albumin-mediated-chemotherapeutic-300495897.html |
The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic,Oncotarget. 2015; 6:31344-31359.,https://doi.org/10.18632/oncotarget.5181 |
Also Published As
Publication number | Publication date |
---|---|
EP3668538A4 (en) | 2021-06-16 |
CA3073045A1 (en) | 2019-02-21 |
KR20200033351A (ko) | 2020-03-27 |
EP3668538A1 (en) | 2020-06-24 |
KR20220068272A (ko) | 2022-05-25 |
AU2018318125A1 (en) | 2020-03-19 |
AU2018318125B2 (en) | 2021-09-09 |
WO2019036485A1 (en) | 2019-02-21 |
KR20230115351A (ko) | 2023-08-02 |
US20230000978A1 (en) | 2023-01-05 |
US11510982B2 (en) | 2022-11-29 |
JP2020531437A (ja) | 2020-11-05 |
US20200237908A1 (en) | 2020-07-30 |
CN110996991A (zh) | 2020-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11439697B2 (en) | Nant cancer vaccine | |
Liu et al. | Turning cold tumors into hot tumors by improving T-cell infiltration | |
JP2019065028A (ja) | 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法 | |
US20230000978A1 (en) | haNK Cetuximab Combinations And Methods | |
US20200352972A1 (en) | Aldoxorubicin combination treatments and methods | |
WO2019152922A1 (en) | Calreticulin and fusion proteins | |
Sayour et al. | Cancer mRNA vaccines: clinical advances and future opportunities | |
US11823773B2 (en) | Nant cancer vaccine strategies | |
US20230034802A1 (en) | Nant Cancer Vaccine | |
Mandal | Cancer Immunotherapy: Extending New Horizons in Cancer Treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200401 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210427 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20210514 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20210521 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210713 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210927 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211027 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220401 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220420 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7062754 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |